Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...

Pfizer’s Hympavzi (marstacimab) has been approved in the European Union (EU) to prevent or reduce the frequency of bleeding episodes in adults and children, ages 12 and older, with severe hemophilia A ...

Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union ...

For those looking for great candidates, here are two in the healthcare sector: Merck ( MRK 2.48%) and Pfizer ( PFE 0.76%).

Data, used for myriad purposes, plays a critical role in life sciences, and cloud-based platforms can ease the organisational ...

Delhi: Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the ...

Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors: New York Thursday, November 21, 2024, 0 ...

The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...

The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.